Key facts
- This page summarizes David R. Purdue's Form 3 filing for AbbVie Inc. (ABBV).
- 0 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 10 Mar 2025, 16:28.
David R. Purdue - 01 Mar 2025 Form 3 Insider Report for AbbVie Inc. (ABBV)
- Reporting relationship
- SVP, Controller
- Issuer ticker
- ABBV
- Reported as of
- 01 Mar 2025
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 10 Mar 2025, 16:28:43 UTC
- Next SEC filing
- 20 Feb 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ T.O. Odutayo, Attorney-in-Fact for David R. Purdue
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
David R. Purdue filed Form 3 for AbbVie Inc. (ABBV) on 10 Mar 2025.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ABBV
holding
Common Stock, $0.01 par value
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 4,505
- Date
- 01 Mar 2025
- Ownership
- Direct
ABBV
holding
Common Stock, $0.01 par value
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 527
- Date
- 01 Mar 2025
- Ownership
- Profit sharing trust
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ABBV
holding
Derivative
Option (Right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,376
- Exercise price
- $149.62
- Footnotes
- F2
ABBV
holding
Derivative
Option (Right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,358
- Exercise price
- $175.28
- Footnotes
- F3
ABBV
holding
Derivative
Option (Right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,208
- Exercise price
- $192.86
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Balance in AbbVie Savings Program as of March 1, 2025. Balance includes shares acquired pursuant to a dividend reinvestment feature.
Footnote F2
Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program. The option became exercisable as to 1,126 shares on 02/16/2024, as to 1,125 shares on 02/16/2025, and will become exercisable as to 1,125 shares on 02/16/2026.
Footnote F3
Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program. The option became exercisable as to 1,786 shares on 02/15/2025, and will become exercisable as to 1,786 shares on 02/15/2026, and as to 1,786 shares on 02/15/2027.
Footnote F4
Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program. The option becomes exercisable as to 1,736 shares on 02/13/2026, as to 1,736 shares on 02/13/2027, and as to 1,736 shares on 02/13/2028.